Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR Alpha/Beta and CD19 Depleted HSCT for Non-Malignant Disorders
NCT03615144Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2018
- Primary completion
- Nov 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of T-cell receptor alpha/beta and CD19 depleted hematopoietic stem cells in sickle cell disease (SCD), beta thalassemia major, bone marrow failure and 2 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Survival at 2 years. Started Jul 2018; status: terminated.
02
Drugs
T-cell receptor alpha/beta and CD19 depleted hematopoietic stem cells
03
Conditions
sickle cell disease (SCD)beta thalassemia majorbone marrow failureautoimmune cytopeniashistiocytic disorders
Beyond the preview
Go deeper on NCT03615144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03615144.